A Phase 1 Single-ascending Dose Study of the Oral Glucocorticoid Receptor Antagonist ORIC-101 in Healthy Adult Subjects

Trial Profile

A Phase 1 Single-ascending Dose Study of the Oral Glucocorticoid Receptor Antagonist ORIC-101 in Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Apr 2018

At a glance

  • Drugs ORIC 101 (Primary)
  • Indications Cancer
  • Focus Adverse reactions
  • Sponsors ORIC Pharmaceuticals
  • Most Recent Events

    • 03 Apr 2018 Status changed from active, no longer recruiting to completed.
    • 12 Dec 2017 Status changed from recruiting to active, no longer recruiting.
    • 31 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top